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Abstract (240 words) 28
Objectives: to give indication of a fitness cost conferred by FKS mutation-associated 29 echinocandin resistance in Candida glabrata during human infection. 30
Methods: six C. glabrata clinical strains sequentially isolated from blood and a hepatic 31 abscess in a solid organ transplant recipient were analysed. The patient had received long-32 term azole and echinocandin therapy for invasive aspergillosis and persistent candidemia. 33
Minimal inhibitory concentrations were determined by the EUCAST broth microdilution 34 method. Molecular mechanism of antifungal resistance was determined by sequencing 35 hotspots of the FKS. Strain relatedness was determined using a microsatellite-based typing 36 method. 37
Results: Importantly, typing analysis showed an identical microsatellite pattern for all 38 isolates, supporting a close relation. The first C. glabrata isolate showed wild type phenotype 39 (i.e. susceptibility to echinocandins and low level of azole resistance). After voriconazole 40 therapy, the C. glabrata acquired pan-azole resistance quickly. Later, echinocandin treatment 41 led to the emergence of a FKS2 S663P alteration and echinocandin resistance. Importantly, 42 after disruption of both azole and echinocandin therapy in favour of liposomal amphotericin 43 B, C. glabrata isolates regained full susceptibility to echinocandin and lost the FKS2 S663P 44 alteration, while nonetheless maintaining their pan-azole resistance. 45 Conclusion: our clinical report supports the potential existence of a fitness cost conferred by 46 FKS mutation in C. glabrata, as disruption of treatment led to a rapid disappearance of the 47 resistant clone. This suggests that a more restricted use and/or a discontinuous administration 48 of echinocandins may limit the spread of clinical resistance to this class. Acquired resistance involving FKS hotspot mutations is a subject of concern, but to date it 110 has only been described in patients who were already receiving echinocandins. In our study, all of the C. glabrata isolates were undistinguishable by genotyping analysis. 116
Extended treatment with caspofungin did not lead to the apparition of Candida with higher 117 echinocandin MICs. Intriguingly, a candidemia breakthrough with the same C. glabrata 118 strain, except for the FKS2 S663P alteration, occurred only seven days after micafungin 119 initiation. So, despite the prolonged period of antifungal therapy, the C. glabrata strain was 120 not replaced by another. Moreover, emergence appeared quickly after treatment initiation 121 while no resistance occurred during the 28-day treatment period with high-dose caspofungin. 122
This might be due at least in part to an insufficient dosage of the drug in this particular patient 123
[12].occult deep lesions. A blood culture sampled 23 days after echinocandin cessation retrieved 127 the same C. glabrata except that it was once again susceptible to echinocandin and lacked the 128 S663P alteration. Interestingly however, its azole resistance profile was not modified. 129
Our report reflects the daily clinical practice of mycologists and physicians and thus has some 130 limitations. We did not perform extensive and exhaustive analyses of the innumerable 131 colonies that grew in our array of blood culture vials and thus may have missed mixed and 132 persistent resistant isolates which might reflect a pooled reservoir, as previously described 133
[13]. Nonetheless, the most important observation is that at that time we were no longer able 134 to detect a resistant isolate. Thus, our report brings an important observation to light that 135 
